Ruzicka v. Secretary of Health and Human Services

In the United States Court of Federal Claims

OFFICE OF SPECIAL MASTERS

No. 17-109V

Filed: November 13, 2023

************************* *

*

FRANCES RUZICKA, *

*

*

Petitioner, *

*

v. *

*

*

SECRETARY OF HEALTH AND *

HUMAN SERVICES, *

*

*

Respondent. *

*

************************* *

Patricia Finn, Patricia Finn, P.C., Nanuet, NY, for Petitioner

Sarah Rifkin, U.S. Department of Justice, Washington, DC, for Respondent

DECISION ON ENTITLEMENT 1

Oler, Special Master:

On January 24, 2017, Frances Ruzicka (“Petitioner” or “Ms. Ruzicka”) filed a petition for

compensation under the National Vaccine Injury Compensation Program, 42 U.S.C. § 300aa-10,

et seq. 2 (the “Vaccine Act” or “Program”). The petition alleges that Ms. Ruzicka developed

fibromyalgia and “post-vaccination syndrome” as a result of the tetanus, diphtheria, and acellular

pertussis (“Tdap”) vaccine she received on July 29, 2014. Pet. at 1, 6, ECF No. 1.

1 Because this Decision contains a reasoned explanation for the action in this case, it must be made publicly

accessible and will be posted on the United States Court of Federal Claims' website, and/or at

https://www.govinfo.gov/app/collection/uscourts/national/cofc, in accordance with the E-Government Act

of 2002. 44 U.S.C. § 3501 note (2018) (Federal Management and Promotion of Electronic Government

Services). This means the Decision will be available to anyone with access to the internet. In accordance

with Vaccine Rule 18(b), Petitioner has 14 days to identify and move to redact medical or other information,

the disclosure of which would constitute an unwarranted invasion of privacy. If, upon review, I agree that

the identified material fits within this definition, I will redact such material from public access.

2 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755. Hereinafter, for ease

of citation, all “§” references to the Vaccine Act will be to the pertinent subparagraph of 42 U.S.C. § 300aa

(2012).

1

Upon review of the evidence in this case, I find that Petitioner has not established by

preponderant evidence that the Tdap vaccine can cause or did cause her symptoms. The petition is

accordingly dismissed.

I. Procedural History

Ms. Ruzicka filed her petition on January 24. 2017. Pet. at 1. She filed medical records in

support of her petition on February 16, 2017 (Exs. 1-4) and April 19, 2017 (Ex. 6). 3 Respondent

submitted his Rule 4(c) Report on September 22, 2017, recommending that “entitlement to

compensation be denied” in this case. Resp’t’s Rep. at 1, ECF No. 20. In his Rule 4(c) Report,

Respondent requested that Petitioner file medical records related to “any rheumatological

assessments prior to her vaccination” at issue in this case. See ECF No. 20 at 1, n. 1.

I held a status conference on September 4, 2018. Respondent articulated reasonable basis

concerns for this claim, stating that it was his position that “post-vaccination syndrome” was not

a recognized injury under applicable case law. Respondent was also unsure as to how an aluminum

adjuvant theory of causation, as proposed by Petitioner’s potential expert in this case, Dr. Yehuda

Shoenfeld, would be different from an autoimmune/inflammatory syndrome induced by adjuvants

(ASIA) theory -- i.e., a theory that has been strongly criticized by special masters in prior Vaccine

Act cases. Petitioner’s counsel stated that, although she had alerted her client about the need to

produce additional medical records that were requested by Respondent in his Rule 4(c) Report

filed on September 22, 2017, she had been unsuccessful in retrieving those records as of the date

of the status conference. After the conference, I ordered Petitioner to file an expert report, as well

as the outstanding records requested by Respondent in his Rule 4(c) Report. Scheduling Order

dated September 4, 2018; ECF No. 33.

Petitioner filed an expert report from Dr. Toni Bark on January 25, 2019. Ex. 6, ECF No.

36. Respondent filed responsive expert reports on September 30, 2019, from Drs. Arnold Levinson

and Carlos Rose. Exs. A, C.

On October 29, 2019, I ordered Petitioner to file any prior rheumatology records. Non-PDF

order dated October 29, 2019. I reiterated this same order on January 2, 2020. See Non-PDF Order

dated January 2, 2020. On February 27, 2020, Petitioner filed a status report, indicating that no

additional prior rheumatology records existed. ECF No. 48.

On April 2, 2020, Petitioner filed a status report informing the Court that Dr. Bark had

passed away on March 2, 2020. ECF No. 49. Petitioner requested an extension of time to locate a

new expert. Id. I granted that request.

On September 3, 2020, Petitioner filed an expert report from Dr. James Lyons-Weiler. Ex.

23. On December 8, 2020, Respondent filed a Motion to Exclude Dr. Lyons-Weiler’s Report. ECF

No. 62. I held a status conference on December 14, 2020, to discuss Respondent’s motion. See

Minute Entry dated 12/16/2020; Scheduling Order dated 12/16/2020. During the status conference,

3 The page numbers in all of the medical record exhibits have two different page stamps. For consistency,

I have referenced the number in the bottom middle of the page throughout this Decision.

2

Petitioner’s counsel indicated she intended to file a motion to strike Dr. Lyons-Weiler’s report and

that she was in the process of securing a different expert. Scheduling Order dated 12/16/2020, ECF

No. 65. I indicated that Dr. Lyons-Weiler’s report would remain in the record for the purpose of

determining fees, however I would not consider it as evidence pertaining to entitlement; the parties

agreed. See id.

On February 15, 2021, Petitioner filed an expert report from Dr. James Neuenschwander.

Ex. 49. The parties then filed a series of responsive expert reports. Exs. 63, 79, E, F, H, I.

The parties filed their respective motions for a ruling on the record and confirmed that the

record is complete. ECF Nos. 87, 88, 89.

On September 26, 2023, I admitted Court Exhibit 1001, which is described below:

On September 5, 2017, Dr. Neuenschwander posted the following comment on WordPress,

a blog hosting platform:

Nowhere else in medicine do we do what we do with vaccines, where we give

everybody that exact same dose of something. And then we’re shocked that we get

some bad outcomes. And we have a vaccine injury court that paid out $3.6 billion,

last I checked, for vaccine injuries.

And when you look at what these vaccine injuries are, most of them are all

symptoms of autism… encephalopathy, seizures, and things along those lines…

and what am I supposed to think? I’m supposed to tell parents that, regardless of

their knowledge, they should vaccinate, just because everyone tell [sic] me to?

I can’t abide by that. I mean, there has to be a way for us to say, these are children

at risk and they just shouldn’t be vaccinated. And because of my experience, I’ve

been doing this for a long time, I’ve gone from being that vaccine Nazi to being

somebody who… I don’t know if there’s a vaccine I would recommend anymore.

— James Neuenschwander, MD

Court Ex. 1001.

I gave Petitioner until October 26, 2023 to file a response to Court Exhibit 1001. See Scheduling

Order dated September 26, 2003; ECF No. 103. Petitioner did not file a response.

This matter is now ripe for an adjudication.

II. Medical Records

A. Relevant Pre-Vaccination History

3

Petitioner was 51 years old when she received the Tdap vaccination on July 29, 2014. See

Ex. 4 at 1. She had a long history of joint pain, “diffuse myalgias,” irritable bowel syndrome

(“IBS”), asthma, and hypothyroidism. See Ex. 2 at 10, Ex. 3 at 32.

Prior to vaccination, on June 20, 2014, Petitioner called her doctor’s office to get a note

exempting her from Tdap vaccine because of a prior reaction she had to the diphtheria-tetanus-

pertussis (“DTP”) vaccine “years ago.” Ex. 2 at 7. Petitioner said she had experienced nausea,

diarrhea, sore joints, and itchy skin when she last received the DTP vaccine. Id. The reaction had

lasted for a few days. Ex. 3 at 21. Dr. Bobek wrote the following note: “Frances A. Ruzicka is a

51-year-old patient of mine who says that years ago she had a ‘DPT’ shot and got sick from it….

Because of this reaction, I ask that Ms. Ruzicka not be required to have a Tdap vaccination.” Ex.

2 at 9. Petitioner’s employer denied the request. Ex. 5 at 3.

Petitioner received a Tdap vaccine on July 29, 2014. Ex. 4 at 1. She emailed her employer

on the same day stating, “I am going to receive this vaccine today against my better judgment. In

the event of any adverse reaction as I have had in the past, I will hold the employer solely

responsible.” Ex. 6 at 6.

B. Post-Vaccination History

On August 4, 2014, Petitioner presented to Dr. James Joseph at Geisinger Elysburg Family

Practice, regarding redness and warmth in her right arm, and reported it was painful, heavy, and

tight. Ex. 2 at 10. She also reported feeling nauseous. Id. Petitioner was diagnosed with cellulitis,

and was instructed to rest and was given Zithromax, an antibiotic. Id. at 11.

On September 10, 2014, Petitioner returned to Geisinger Elysburg Family, and was seen

by Dr. Francis Bobek, her primary care physician (“PCP”). Ex. 2 at 18. Dr. Bobek’s summary of

Petitioner’s prior history is as follows:

The patient has not felt well since she had a Tdap vaccination on Jul 29 2014 in the

right deltoid area. The patient missed work on Jul 30, 31 and August 1 because of

not feeling well after the vaccination. The patient had headache sore throat and joint

pains. The patient was seen by my associate on August 4 because of a red warm

swollen tender right shoulder. She was diagnosed as cellulitis and reaction to

vaccination. The patient was treated with azithromycin and her warm red swollen

shoulder resolved.

However the patient has continued to have intermittent problems which include

pains in the joints. She currently is bothered by pains in the elbows wrists shoulders

and hips. She says she feels pain in the bilateral greater trochanteric areas of the

hips. She has also had a headache on and off since … vaccination. In the last few

days she has developed tingling in the hands and feet bilaterally. She … also noticed

worsening of her headache which is mostly in the neck and occipital area…. The

patient feels very stressed because of the persistence of symptoms since the

vaccination.

4

Id. at 18-19. On physical examination, Dr. Bobek noted “bilateral point tenderness in the lateral

epicondylar areas. She has tenderness with palpation of the bilateral trochanteric bursa areas. She

has pain deep in the deltoids with internal external rotation of the shoulders bilaterally. The joints

are not red warm or swollen.” Id. at 20. Dr. Bobek diagnosed Petitioner with a “post-vaccination

reaction” and elevated blood pressure and paresthesias and recommended Petitioner return for a

follow-up in a week. Id. at 21.

On September 17, 2023, Petitioner returned to discuss her symptoms and bloodwork results

with Dr. Bobek. Ex. 2 at 44. Petitioner’s thyroid-stimulating hormone (“TSH”) was elevated;

Petitioner informed Dr. Bobek “that she had head pounding in the past when she was on higher

doses of thyroid medicine years ago. Because of that side effect she discontinued the thyroid

medicine and, per her personal report, has been hypothyroid for least 10 years. The patient is

willing to try a low dose of thyroid replacement therapy.” Id. Dr. Bobek also noted in the “Post

vaccination syndrome” section, that Petitioner’s right shoulder swelling and redness had resolved

but Petitioner had increased “skin and muscle sensitivity in her proximal upper and lower

extremities and torso.” Id. Petitioner reported a “fire-like” sensation when running her hands over

the skin of her extremities and torso. Id. Petitioner reported a history of numbness and tingling in

her hands and feet. Id. at 47. On physical exam, Dr. Bobek noted Petitioner had some pain with

palpations of the arm muscles as well as thigh muscles and abdominal and back muscles, and that

Petitioner was angry that her symptoms developed post vaccination and was anxious about

worsening symptoms in the future. Id. Dr. Bobek listed hypothyroidism as the primary encounter

diagnosis, but included “serum reaction due to vaccination” and paresthesia, and prescribed

Petitioner levothyroxine 4 and prednisone. Id.

On October 2, 2023, Petitioner messaged Dr. Bobek for a neurology consult. Ex. 2 at 69-

70. On October 4, 2014, Petitioner and Dr. Bobek met to follow up on her ongoing issues. Id. at

72. Petitioner’s latest symptoms included chronic sore throat, persistent bilateral torso pain,

chronic left greater than right ankle joint pain, and transient swelling and discoloration of the left

ankle, continued paresthesias in the thighs, left hand numbness while driving, impaired sleep,

increased acid reflux, transient chest heaviness, and chronic anxiety. Id.

On November 3, 2014, Petitioner returned to Dr. Bobek for a follow up. Ex. 2 at 86-89.

Petitioner was resistant to increasing her thyroid medications, but Dr. Bobek warned that her

untreated hypothyroidism could complicate her symptoms and lead to neurologic, psychiatric,

metabolic, and orthopedic issues. Id. at 86. Petitioner agreed to increase her levothyroxine dosage.

Id. Petitioner reported “migratory sharp pains and paresthesias in [her] arms and legs,” including

a shooting pain sensation when she turned a doorknob, as well as swelling in her ankles that comes

and goes. Id. Petitioner refused treatment for her anxiety despite biting her nails and fingers. Id.

On physical examination, Petitioner had “some tenderness with palpation of the ulnar groove in

4 Levothyroxine sodium: the monosodium salt of l-thyroxine, the naturally occurring form of thyroxine,

obtained from the thyroid gland of domesticated food animals or prepared synthetically. It is used as

replacement therapy for hypothyroidism and in the prophylaxis and treatment of goiter and of thyroid

carcinoma, administered orally, intramuscularly, or intravenously. DORLAND’S MEDICAL DICTIONARY

ONLINE, www.dorlandsonline.com/dorland/definition?id=28172&searchterm=levothyroxine+sodium (last

visited Aug. 8, 2023) (“DORLAND’S”).

5

the medial left elbow area.” Id. at 88. Dr. Bobek recommended following up in three months. Id.

at 89.

On November 5, 2014, Petitioner presented to Geisinger-Bloomsburg Hospital for a

neurology consult. Ex. 3 at 3-4. She was seen by Dr. Joseph Alario, D.O., a neurology resident,

who dictated notes from this appointment, and Dr. Uzzal Roy, M.D., a neurologist, who observed.

Id. at 7. Dr. Alario’s note consisted of the following observations: “chief complaint of muscle

soreness and abnormal pain sensation and her history and physical exam [] may be a post

vaccination syndrome, but with low thyroid may have prolonged recovery, no evidence of a central

nervous system process and normal ANA and ESR are reassuring. The complaints of shooting pain

in her elbows is concerning for left ulnar neuropathy.” Id. at 6. Petitioner’s neurological exam was

largely normal. Id. at 6. It was recommended that Petitioner follow up in three months or call if

any symptoms worsened.

On January 5, 2015, petitioner saw Dr. Todd Preston, an otolaryngologist. Ex. 3 at 21. She

reported a sore throat with globus sensation, dry cough, and hoarseness that started five months

ago after she received a Tdap vaccine. Id. Dr. Preston assessed Petitioner with “[n]ew onset of

GERD symptoms unlikely related to vaccination.” Id. at 23. He further stated that “It is extremely

unlikely for this pt to be suffering from post-vaccination reaction 6-7 mo after injection, and almost

impossible for this to be related to GERD lesions. [With] the host of systemic symptoms, a

systemic process is more likely.” Id.

Petitioner was seen by Dr. Alfred Denio, M.D., a rheumatologist, on January 20, 2015. Ex.

3 at 31-33. Petitioner was referred to Dr. Denio by Dr. Bobek for her “diffuse arthralgias, myalgias,

and paresthesias.” Id. at 31. It was Dr. Denio’s impression that Petitioner had fibromyalgia, and

that it was “fairly typical by history and physical, appears to have been triggered by a reaction to

a Tdap vaccine last July…. In reviewing her previous history, she has had episodes of diffuse

discomforts over the years. No indication of a Guillain-Barre or other radiculopathy as her

neurologic exam is normal. No evidence of an inflammatory arthritis. She seems to be under a lot

of stress currently.” Id. Dr. Denio noted that Petitioner’s fibromyalgia “appears to have been

triggered by a reaction to a Tdap vaccine last July.” Id.

On March 25, 2015, Petitioner saw neurologist, Dr. Scott Friedenberg at Geisinger

Neurology. Ex. 3 at 53-54. Dr. Friedenberg noted that Petitioner had a history of:

many years of multiple multifocal neurologic symptoms without etiology

identified, sx ppt by recent vaccine? And her flare ups of disease are short lived in

past, with vaccination sx have persisted.

Pt with clinical history of fibromyalgia based on normality of clinical exam and

significance of myofascial pain. Continues with joint sx, muscle aches, numbness,

fatigue. Finds she has trouble at work with opening bags. After day of work she is

very sore and fatigued, wants to be away from people (reports leaving her

grandsons birthday party due to discomfort and despondence about her sx).

Id. at 53. It was Dr. Friedenberg’s impression that Petitioner had fibromyalgia and recommended

6

a trial of medication to which Petitioner stated “I’m not a pill taker and I won’t take anything.” Id.

at 54. He recommended testing for Sjogren’s syndrome and small fiber neuropathy but opined, “I

suspect she does not have any other diagnosis.” Without additional testing, Dr. Friedenberg

believed that fibromyalgia was Petitioner’s diagnosis. Because Petitioner refused additional testing

and treatment, Dr. Friedenberg believed he was at a standstill. Id. Petitioner requested a referral to

a pain management clinic. Id.

On May 13, 2015, Petitioner returned to Dr. Bobek for her ongoing issues. Ex. 2 at 129-

32. Petitioner complained of chronic pain in her ankles, knees, hips, glutes, elbows, wrist, hands,

back and thighs, which Dr. Bobek classified as part of Petitioner’s fibromyalgia. Id. at 129. These

pains gave her difficulties at work. Id. Petitioner reported that she had stopped taking her thyroid

medication in March and noticed reduced hand swelling, breast tenderness and swelling, weight

gain, and nausea. Id.

On June 2, 2015, Petitioner went to the Gsach-Geisinger Shamokin Emergency Room for

“substernal chest heaviness on and off for the last week, non-radiating, associated with dyspnea,5

nausea, burning sensation that radiates up her chest. States 2 weeks ago she hooked herself up to

the monitor… and she did not have a LBBB 6… She is very concerned she has an ulcer.” Ex. 3 at

107. Her tests and lab work indicated nothing abnormal, and she was discharged. Ex. 2 at 155-57.

She saw her PCP on June 11, 2015, to follow up on her chest pain. Ex. 2 at 155. Dr. Bobek

noted Petitioner had an extensive cardiac work up and no cardiac disease was identified. Id.

Petitioner also presented concern for her work as she was having difficulty lifting patients with her

fibromyalgia pain. Id. She insisted that she did not take medication for either her fibromyalgia or

anxiety, but was willing to receive psychological counseling. Id. She further denied medication for

her hyper cholesterol. Id.

On November 25, 2015, Petitioner returned to Dr. Bobek still reporting widespread

myalgias, poor sleep, muscle twitching, ankle swelling, mental sluggishness, and constant fatigue.

Ex. 2 at 188.

On December 7, 2015, Ms. Ruzicka returned to Dr. Bobek for a follow-up regarding her

fall from several days prior. Ex. 2 at 199-203. Petitioner reported that she had sprained her ankle

falling down the stairs, and went to the emergency room for treatment. Id. She was given a brace

and was walking with crutches, but felt like she could not bear any weight on her right ankle. Id.

She was given a smaller ankle brace and a physical therapy referral. Id. at 203.

5Dyspnea is “breathlessness or shortness of breath; difficult or labored respiration.” DORLAND’S,

www.dorlandsonline.com/dorland/definition?id=15277&searchterm=dyspnea (last visited Oct. 31, 2023).

6 LBBB stands for “left bundle branch block.” A bundle branch block is “interruption of conduction in one

of the main bundle branches [of the heart], left or right; the sequence of ventricular depolarization is altered

since the impulse reaches one ventricle and then travels to the other.” DORLAND’S,

https://www.dorlandsonline.com/dorland/definition?id=60753 (last visited Nov. 7, 2023).

7

On September 10, 2019, Petitioner saw Christopher Whiting, D.O., a neurologist. Ex. 21

at 1. She reported that since her Tdap vaccination, she had experienced intermittent

numbness/tingling, joint pain, muscle aches, an intermittent rash, a tendency to drop things, dry

eyes, dry mouth, weakness in her legs, tinnitus, post-traumatic stress, anxiety and depression. Id.

at 1-2. Petitioner reported that she was “not interested in taking any medications for symptoms

except CBD and medical marijuana.” Id. at 2. Petitioner’s neurologic exam was entirely normal

except that Dr. Whiting documented her gait and Romberg 7 as unsteady. Id. at 5-6. Dr. Whiting

suggested that petitioner “consider a skin biopsy to rule out small fiber neuropathy.” Id. at 7. There

is no indication that Petitioner obtained the recommended biopsy.

On January 13, 2020, Petitioner visited Emily Brunner, D.O., a rheumatologist. Ex. 22 at

5. The HPI describes that Petitioner is a “57 year old female with [history] of fibromyalgia, anxiety,

cyclic nausea, hypothyroidism (untreated), [hypertension] (untreated) who is referred for

myalgias.” Id. At this visit, Petitioner described “generalized pain of the muscles, joints, and

nerves” for five and one half years. Id. She was concerned there was “something being missed” by

her physicians and was further concerned that she had multiple sclerosis. Id. An EMG performed

in 2019 was normal, and a brain MRI showed nonspecific degenerative changes. Id. A prior

neurologist mentioned “possible small fiber neuropathy.” Id. Dr. Brunner noted that Petitioner’s

blood pressure was “markedly elevated,” at 210/100. Id. Further, her TSH level was elevated at

54.02 ulU/ml. Id. at 9. Petitioner indicated that her hypothyroidism was untreated and that she did

not plan to take medication for it. Id. at 10. Dr. Brunner documented that Petitioner experienced

“a chronic widespread pain with heightened pain response, and often associated with fatigue, poor

sleep, IBS, and anxiety. Her current presentation is still very fitting of this diagnosis,

[fibromyalgia] and do not suspect another autoimmune or inflammatory diagnosis at this time.”

Id. Finally, Dr. Brunner documented: “Presentation most consistent with FMS. Likely her

symptoms are in part made worse by untreated hypothyroidism.” Id.

No other relevant medical records were submitted.

III. Petitioner’s Affidavit

Petitioner signed her affidavit on January 3, 2017. Ex. 1 at 3. Petitioner stated two days

after receiving her July 29, 2014, Tdap vaccine, she called to work to request sick leave because

of flu-like symptoms, sore muscles and joints, headaches, nausea and vomiting, sore throat, and

soreness and redness at the injection site. Id. at 1.

Petitioner reported that her symptoms got worse after taking antibiotics, but her cellulitis

resolved. Id. Petitioner mentioned that her neurological symptoms increased in frequency and

duration, and numbness spread to her lower and upper extremities. Id. Petitioner also developed a

sensitivity to touch. Id. at 2.

7 Romberg sign is “swaying of the body or falling when standing with the feet close together and the eyes

closed; the result of loss of joint position sense, seen in tabes dorsalis and other diseases affecting the

posterior columns.” DORLAND’S, www.dorlandsonline.com/dorland/definition?id=106448 (last visited

Nov. 2, 2023).

8

Petitioner saw her PCP, Dr. Francis Bobek on September 10, 2014 out of concern for her

symptoms worsening. Ex. 1 at 2. Dr. Bobek diagnosed Petitioner with “post-vaccination

syndrome,” which resulted in Petitioner being unable to work for 11 weeks. Id.

Petitioner next saw rheumatologist Dr. Alfred Denio on January 20, 2015, and was

diagnosed with fibromyalgia triggered by the Tdap vaccination she received on July 29, 2014. Ex.

1 at 2. She continues to experience nausea, dizziness, insomnia, numbness and tingling in her

extremities, sore muscles, joint and nerve pain, fatigue, chronic sore throat resulting in difficulty

swallowing, and muscle spasms. Id. As a result, Petitioner cannot perform normal day-to-day

activities such as holding items like a shopping bag or cellphone or opening bottles or cans. Id.

She can only walk short distances, experiences “fibro fog,” and can no longer lift heavy objects.

Id. at 2-3.

While at work on June 5, 2015, Petitioner experienced chest pain that required her to be

taken to Geisinger Medical Center, where she was informed that she experienced a heart attack

and left bundle branch block. Ex. 1 at 2.

On December 3, 2015, Petitioner fell down the stairs due to numbness in her legs, which

resulted in three torn ligaments in her right ankle. Ex. 1 at 2. Petitioner has missed a total of seven

months of work due to her alleged vaccination injuries. Id. She is also only able to work a four

hour shift three to four days per week. Id. at 3.

IV. Expert Opinions and Qualifications

A. Petitioner’s Expert: Dr. Toni Bark, M.D.

Dr. Bark received a B.S. in psychology from the University of Illinois in 1981 and received

her medical degree from Rush Medical College in 1986. Ex. 7 (“Bark CV”) at 1. Dr. Bark

completed residencies in rehabilitative medicine and pediatrics and received a M.S. in healthcare

emergency management in 2012. Id. Dr. Bark also held a number of hospital and clinical positions

over two decades and previously served as the Medical Director and owner of the Center for

Disease Prevention in Evanston, Illinois. See Bark CV at 1-2.

Dr. Bark filed one expert report in this case. Ex. 6 (hereinafter “Bark Rep.”). In her report,

Dr. Bark pointed to the aluminum hydroxide component of the Tdap vaccine as the “logical cause”

and as “sequentially connected to petitioner’s injuries.” Bark Rep. at 2. Dr. Bark stated that

Petitioner had been diagnosed by her treating physician as having “a vaccine-induced Myalgic

Encephalomyelitis/Chronic Fatigue Syndrome [ME/CFS] and fibromyalgia.” Id. at 3. She

elaborated on her proposed causal mechanism, opining that Petitioner suffered from “endoplasmic

reticulum (ER) HyperStress induced autoimmunity… from a combination of genetics risk factors

… coupled with environmental exposures (aluminum hydroxy), which together can cause cellular

death and pathological outcomes experienced by petitioner.” Id.

Dr. Bark opined that the endoplasmic reticulum stress leads to an accumulation of unfolded

proteins, which causes a reduction of general protein translation rate, an increase in expression of

endoplasmic reticulum chaperones, and the onset of protein degradation. Bark Rep. at 4. She

9

opined that aluminum causes ER hyperstress. Id. She further opined that “[a]ny environmental

factors that induces [sic] ER HyperStress (TDaP) will interact with genetic ER Hyperstress, and

the effects can influence both the production of molecular mimicry and deranged immune function

as occurred in petitioner’s case.” Id. at 5. Dr. Bark concluded by stating “the theory of aluminum-

induced ER Hyperstress as playing an important role in the petitioner’s individual case of vaccine-

induced autoimmunity is more likely than not the cause of the vaccine injuries she sustained and

the sequala to those injuries.” Id. at 6.

B. Petitioner’s Expert: Dr. James Neuenschwander, M.D.

Dr. Neuenschwander received a B.S. in cellular and molecular biology in 1981 and his

medical degree in 1985, both from the University of Michigan. Ex. 50 (“Neuenschwander CV”)

at 1. He also participated in three years of a general surgery residency program at the University

of Michigan before voluntarily leaving to pursue an integrative medicine practice and founding

Bio Energy Medical Center. Id. Dr. Neuenschwander is board certified in emergency medicine

and certified by the American Board of Integrative and Holistic Medicine. Id. at 3.

Dr. Neuenschwander filed two reports in this case. Exs. 49, 63. In his first expert report,

Dr. Neuenschwander disagreed with Dr. Bark regarding Petitioner’s diagnosis. Ex. 49 (“First

Neuenschwander Rep.”) at 1. Dr. Neuenschwander opined that Petitioner’s symptoms were

consistent with small fiber neuropathy and fibromyalgia; not ME/chronic fatigue syndrome as

posited by Dr. Bark. Id.

He stated that the onset of Petitioner’s symptoms began with hyperesthesia, which started

a few days after her severe local reaction to the Tdap vaccine. First Neuenschwander Rep at 2. Dr.

Neuenschwander opined that Petitioner’s initial response was not cellulitis, but instead was a

“classic over-reaction of her immune system to the adjuvant in the vaccine.” Id.

Dr. Neuenschwander opined that Petitioner suffers from small fiber neuropathy (“SFN”)

and fibromyalgia. First Neuenschwander Rep. at 3. Dr. Neuenschwander stated “It is likely that

Francis had a significant predisposition for SFN based on her Hashimoto’s history and her TDaP

vaccination was the precipitating event that cause[d] her fibromyalgia and SFN pain symptoms

resulting in her current state of disability.” Id. at 4.

Dr. Neuenschwander then focused his first expert report on the connection between

aluminum adjuvants and Petitioner’s development of symptoms. He opined that aluminum is a

neurotoxin and noted that the Agency for Toxic Substances and Disease Registry set a minimal

risk level for intake of oral aluminum at 1mg/kg/day. First Neuenschwander Rep. at 4-5. He further

stated that injected aluminum, unlike inhaled and IV aluminum which are eliminated quickly,

forms a depot of particles in the body’s tissues. Id. at 5. Dr. Neuenschwander stated that the oral

absorption of aluminum is approximately 0.3%, while the absorption of aluminum from a vaccine

is approximately 100%. Id. Accordingly, Petitioner’s Tdap vaccine contained the equivalent of

130mg of oral aluminum, twice the minimal risk level for neurotoxicity. Id.

The excess aluminum from the Tdap vaccine caused Petitioner’s immune system to

become over activated. First Neuenschwander Rep. at 5. This overactivation led to oxidative stress.

10

Id. In Petitioner, this normally temporary process became chronic – or what Dr. Neuenschwander

referred to as persistent oxidative stress. Id. at 6. Dr. Neuenschwander further opined that persistent

oxidative stress plays a role in SFN and fibromyalgia. Id.

In his second expert report, Dr. Neuenschwander summarized his causation theory as

follows: “The mechanism involves a vaccine induced immune activation exacerbating an already

existing immune dysfunction resulting in an autoimmune or immune activation process that

subsequently caused a small fiber neuropathy/fibromyalgia type syndrome.” Ex. 63 (“Second

Neuenschwander Rep.”) at 5.

Dr. Neuenschwander based his opinion regarding Petitioner’s correct diagnosis on his

emergency medicine experience. Second Neuenschwander Rep. at 1. He opined that Petitioner

“has the classic presentation of a patient suffering from SFN” beginning with hypersensitivity to

touch and progressing to a pain syndrome. Id. Dr. Neuenschwander downplayed the importance

of intra-epidermal nerve fiber density testing, noting that the test has a false negative rate in the

10-20% range, and that few SFN patients receive this testing. Id. at 2. Ultimately, Dr.

Neuenschwander stated that he based his diagnosis of Petitioner on “the fact that a high percentage

of patients with fibromyalgia have SFN along with the fact that her clinical picture fits the

description of pain caused by SFN.” Id.

Dr. Neuenschwander concluded his second report by reiterating his opinion that Petitioner

was injured by the Tdap vaccine, that her injury has persisted, and that she satisfies all three of the

Althen prongs. Second Neuenschwander Rep. at 5.

C. Respondent’s Expert: Dr. Aaron Levinson, M.D.

Dr. Levinson received his medical degree from the University of Maryland in 1969. Ex. B

(“Levinson CV”) at 1. Dr. Levinson is currently an emeritus professor of medicine and neurology

at the University of Pennsylvania, and formerly served as the Director of the Penn Center for

Clinical Immunology at the University of Pennsylvania School of Medicine and Chief of Allergy

and Immunology at the Philadelphia Veteran Administration Medical Center. Id. at 2. Dr. Levinson

is board certified in internal medicine and allergy and clinical immunology. Id. In 2011, Dr.

Levinson received a Distinguished Service Award from the American Academy of Allergy,

Asthma, and Immunology. Id. at 3. He served on the editorial board for the Journal of Allergy and

Clinical Immunology and Journal of Clinical Immunology and was guest reviewer for a number

of publications, including, Clinical Immunology, Journal of Immunology, Annals of Internal

Medicine, and Journal of Neuroscience. Id. at 4. Dr. Levinson was a consultant to a number of

pharmaceutical companies and advisory panels and served on academic committees at the

University of Pennsylvania. Id. at 4-5. He has delivered a number of lectures at symposiums around

the world. Id. at 6-9. Dr. Levinson has published over 100 peer-reviewed papers and over 40 book

chapters, editorials, and reviews. Id. at 10-21.

Dr. Levinson filed three expert reports in this case. Exs. A (“First Levinson Rep.”), E,

(“Second Levinson Rep.”), and H (“Third Levinson Rep.”).

11

Dr. Levinson agreed that Petitioner suffers from fibromyalgia and described Petitioner’s

symptoms as classic for the disorder. First Levinson Rep. at 6. These symptoms included

widespread pain on both sides of the body, neck pain, back and pelvis pain, along with trigger

points on physical exam, a feeling of pins and needles, hypersensitivity to touch, a swollen feeling

in the hands and feet, headaches, irritable bowel syndrome, fatigue, anxiety, and depression. Id.

Dr. Levinson opined that Dr. Denio’s records suggest Petitioner developed fibromyalgia before

vaccination, but because these earlier rheumatology records were not filed, it is impossible to know

for sure. Id. at 7.

Dr. Levinson disagreed with Dr. Bark that Petitioner either had or was ever diagnosed with

ME/CFS. First Levinson Rep. at 7. He cited a 2015 study that developed diagnostic guidelines for

this condition. Id. at 10. 8 In order to be diagnosed with ME/CFS, a patient must experience the

following three symptoms:

1. A substantial reduction or impairment in the ability to engage in pre-illness levels

of occupational, educational, social, or personal activities that persists for more than

6 months and is accompanied by fatigue, which is often profound, is of new or

definite onset (not lifelong), is not the result of ongoing excessive exertion, and is

not substantially alleviated by rest;

2. Post-exertional malaise; and

3. Unrefreshing sleep.

At least one of the following two manifestations is also required:

1. Cognitive impairment or

2. Orthostatic intolerance

Frequency and severity of symptoms should be assessed. The diagnosis of ME/CFS

should be questioned if patients do not have these symptoms at least half of the time

with moderate, substantial, or severe intensity.

IOM Criteria at 6. In analyzing these criteria, Dr. Levinson concluded that because cognitive

impairment and orthostatic intolerance were not central features in Petitioner’s condition, ME/CFS

was not an appropriate diagnosis. First Levinson Rep. at 11.

Dr. Levison discussed the components of the Tdap vaccine and noted that “[c]ommon side

effects of Tdap include pain and swelling at the injection site, low-grade fever, headache, malaise,

abdominal discomfort including nausea, vomiting or diarrhea, myalgias, and lymphadenopathy.”

First Levinson Rep. at 7. He noted that uncommon side effects include allergic reaction. Id.

Dr. Levinson then discussed the aluminum component of the Tdap vaccine. He noted that

aluminum is an abundant element that is frequently encountered in the environment. First Levinson

Rep. at 8. Average adults ingest 7-9 milligrams of aluminum per day. Id. Alum, an aluminum

8 citing, COMM. ON THE DIAGNOSTIC CRITERIA FOR MYALGIC E NCEPHALOMYELITIS/CHRONIC FATIGUE

SYNDROME, INST. OF MED., BEYOND MYALGIC E NCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME:

REDEFINING AN ILLNESS (2015) (filed as Ex. A, Tab 3) (“IOM Criteria”).

12

compound, is added to vaccines in order to boost the immune response. Id. He noted that the

quantity of aluminum in vaccines is low, and is “miniscule” when compared with the amount of

aluminum ingested each day. Id. Both the National Vaccine Program Office and the Global

Advisory Committee on Vaccine Safety (part of the World Health Organization) have reviewed

studies on aluminum-containing vaccines and have determined there is “no evidence of health risks

that would require changes to vaccine policy.” Id. at 9. The Tdap vaccine contains .33 mg of

aluminum per dose. Id.

Dr. Levinson disagreed with Dr. Bark that the aluminum hydroxide in the vaccine caused

the development of Petitioner’s fibromyalgia. First Levinson Rep. at 12. He further stated: “I am

not aware of any scientific literature that indicates that alum in a species-adjusted dose to that of

< 0.33 mg (amount of aluminum hydroxide in a human Tdap dose) induces autoimmune disease

in an experimental animal.” Id. at 13. Dr. Levinson similarly disagreed with Dr. Neuenschwander’s

assertions about aluminum, opining that he “offers no evidence that toxicity can be induced by the

amount of aluminum in a single vaccine.” Second Levinson Rep. at 4. Dr. Levinson likewise found

Dr. Neuenschwander’s theory to be implausible, noting it is unclear “why a single intramuscular

injection of an aluminum-containing Tdap vaccine would lead to a chronic persistent ER hyper-

stress response that caused oxidative stress in remotely located small somatic fibers and autonomic

fibers and not large somatic fibers.” Id. at 6.

Dr. Levinson also disagreed with Dr. Bark’s proposed causal theory. First Levinson Rep.

at 13. According to Dr. Levinson, Dr. Bark opined that “the ER hyperstress mechanism induced

autoimmunity as a consequence of the so-called unfolded protein response (UPR).” Id. He

described Dr. Bark’s opinion as “very curious” and “quite tangential to this case” because there

has been no evidence presented that any of Petitioner’s conditions were caused by an autoimmune

process. Id. He also criticized the medical literature cited by Dr. Bark and noted that none of the

literature discussed how the Tdap vaccine could have caused chronic ER stress in Petitioner’s

tissues. Id. at 14-15.

Dr. Levinson concluded his first report by opining as follows:

First, for the reasons already stated in my report, Dr. Bark has failed to reliably

support her vaccine causality theory in this case. Second, she failed to show that

Mrs. Ruzicka’s chronic debilitating symptoms were a manifestation of an

underlying autoimmune disease. Third, she failed to reliably explain how her

chronic symptoms might have been caused by aluminum-induced hyperstress-

related mechanisms allegedly induced by a single intramuscular injection of Tdap

and 4) even if she did suffer from CFS/ME, there is absolutely no evidence that

reliably links aluminum to the pathogenic UPR reported in patients with this

syndrome.

First Levinson Rep. at 17.

D. Respondent’s Expert: Dr. Carlos Rose, M.D., C.I.P.

13

Dr. Rose received his medical degree from the University of Buenos Aires School of

Medicine in Argentina in 1977. Ex. D (“Rose CV”) at 1. He completed a residency in internal

medicine and a fellowship in adult rheumatology at the University of Buenos Aires Hospital. Id.

at 5. Dr. Rose then went on to a pediatric residency at Thomas Jefferson University, in

Philadelphia, which was followed by a fellowship in pediatric rheumatology at Children’s Hospital

of Philadelphia, and a year of rotation focused on rheumatology at DuPont Children’s Hospital in

Wilmington, Delaware. Id. at 2. Dr. Rose is board-certified in pediatrics as well as pediatric and

adult rheumatology. Id. at 3-4, 5-6. He has been a practicing physician for 40 years. Ex. C (“Rose

Rep.”) at 1.

Dr. Rose filed one expert report in this case. In that report, he agreed that Petitioner suffered

from fibromyalgia. Rose Rep. at 8. Dr. Rose described that widespread pain distribution,

hyperalgesia, subjective swelling, and paresthesias, are all typical of fibromyalgia. Id. at 9. He

further noted that Dr. Denio described paresthesias, diffuse myalgia, and arthralgia as symptoms

Petitioner had experienced in the distant past. Id. He opined that Petitioner’s fibromyalgia

symptoms “preceded her disease for years.” Id. at 12.

Fibromyalgia is considered a primary pain syndrome and not an inflammatory disease.

Rose Rep. at 9. This point is supported by the fact that the most common treatment modalities for

fibromyalgia are Cymbalta and Lyrica, which target pain modulation, as well as cognitive

behavioral therapy. Id. at 9-10. The mechanisms that are involved in the pathogenesis of

fibromyalgia take years to develop, not days or weeks. Id. at 12.

Dr. Rose discussed different clinical syndromes associated with hypothyroidism. Rose

Rep. at 11. These include rheumatoid arthritis-like disease, pseudogout-like episodes,

hyperuricemia-rarely gout, flexor tenosynovitis of the hand, carpal tunnel syndrome, and proximal

myopathy. Id. In addition, patients with hypothyroidism may also develop “fibromyalgia-like

symptoms”. Id. at 12. Dr. Rose theorized that Petitioner’s hypothyroidism contributed to her

musculoskeletal symptoms. He stated that “carpal tunnel and other nerve entrapment syndromes

associated with acroparesthesia (paresthesia in fingers and toes) are quite typical of

hypothyroidism and can be responsible for up to 70% of carpal tunnel syndrome.” Id.

Ultimately, Dr. Rose opined that Petitioner developed fibromyalgia before her Tdap

vaccination, and that there is no plausible relationship between the vaccine and that disease. Rose

Rep. at 13.

E. Respondent’s Expert: Dr. Lan Zhou, M.D., Ph.D.

Dr. Zhou received his medical degree from Shanghai Medical University in 1989 and his

Ph.D. in developmental biology from the University of Cincinnati in 1995. Ex. G (“Zhou CV”) at

1. Dr. Zhou is currently a professor of neurology and pathology, and vice chair of research at the

Boston University School of Medicine. Id. He is board certified in neurology, nerve and muscle

pathology, and neuromuscular medicine. Id. at 2.

Dr. Zhou filed two expert reports in this case. Exs. F (“First Zhou Rep.”) and I (“Second

Zhou Rep.”). His first report was filed in response to Dr. Neuenschwander. First Zou Rep. In the

14

report, Dr. Zhou stated that Dr. Neuenschwander’s diagnosis of small fiber neuropathy was

erroneous. Id. at 8. Dr. Zhou opined that diagnosis of SFN should include a combination of signs,

symptoms, and diagnostic testing. Id. at 7. He discussed several of Petitioner’s normal physical

exams and that they suggested she did not suffer from SFN. Id. Dr. Zhou specifically stated:

“While the symptoms and signs may suggest small fiber dysfunction, the exams did not

consistently show abnormal sensory findings in the same locations, some of her symptoms were

transient and migrating, so … the diagnosis of small fiber neuropathy cannot be established

without confirmatory test findings.” Id. He described intra-epidermal nerve fiber density testing

(IENFD) as “the gold standard diagnostic test for small fiber neuropathy.” Id. at 8. Although

Petitioner was offered skin biopsy testing, she refused the test. Id. at 8.

Dr. Zhou also opined that there was no causal link between the Tdap vaccine and SFN.

First Zhou Rep. at 8-9.

Dr. Zhou discussed Petitioner’s history of poorly controlled hypothyroidism. On

September 11, 2014, Petitioner’s TSH was measured at 78.62 ulU/mL, where a normal result is

between 0.27 to 4.2 ulU/mL. First Zhou Rep. at 9; Ex. 2 at 32. Dr. Zhou pointed out that

Petitioner’s result was 18.7 times higher than the upper normal limit. Further, Dr. Zhou noted that

Petitioner’s thyroid levels continued to remain elevated. Id. at 10. For example, on January 20,

2015, Petitioner’s TSH was measured at 26.5 ulU/mL. Id.; Ex. 2 at 105. Dr. Zhou stated it is known

that hypothyroidism can cause myalgia and fatigue, and sometimes, more severe myopathy. First

Zhou Rep. at 10; citing Sindoni et al., Hypothyroid myopathy: A peculiar clinical presentation of

thyroid failure. Review of the literature, 17 REV ENDOCR METAB DISORD 499-516 (2016) (filed as

Ex. F, Tab 7) (hereinafter “Sindoni”). Hypothyroidism can also cause neuropathy, including SFN.

First Zhou Rep. at 10; citing Devigili et al., The diagnostic criteria for small fibre neuropathy:

from symptoms to neuropathology, 131 BRAIN 1912-25 (2008) (filed as Ex. F., Tab 3) (hereinafter

“Devigili-1”); Khan & Zhou, Characterization of Non-Length-Dependent Small-Fiber Sensory

Neuropathy, MUSCLE & NERVE 86-91 (2012) (filed as Ex. F, Tab 8) (hereinafter “Khan & Zhou”).

In his second report, Dr. Zhou reiterated that Petitioner did not suffer from small fiber

neuropathy, Petitioner’s symptoms were not connected to the Tdap vaccine, and that Petitioner’s

uncontrolled thyroid condition could have caused her symptoms. Second Zhou Rep. at 1.

V. Applicable Law

A. Petitioner’s Burden in Vaccine Program Cases

Under the Vaccine Act, when a petitioner suffers an alleged injury that is not listed in the

Vaccine Injury Table, a petitioner may demonstrate that she suffered an “off-Table” injury.

§ 11(c)(1)(C)(ii).

In attempting to establish entitlement to a Vaccine Program award of compensation for an

off-Table claim, a petitioner must satisfy all three of the elements established by the Federal Circuit

in Althen v. Sec’y of Health & Hum. Servs., 418 F.3d 1274 (Fed. Cir. 2005). Althen requires that

petitioner establish by preponderant evidence that the vaccination she received caused her injury

“by providing: (1) a medical theory causally connecting the vaccination and the injury; (2) a logical

15

sequence of cause and effect showing that the vaccination was the reason for the injury; and (3) a

showing of a proximate temporal relationship between vaccination and injury.” Id. at 1278.

Under the first prong of Althen, petitioners must provide a “reputable medical theory,”

demonstrating that the vaccine received can cause the type of injury alleged. Pafford, 451 F.3d at

1355-56 (citations omitted). To satisfy this prong, a petitioner’s theory must be based on a “sound

and reliable medical or scientific explanation.” Knudsen v. Sec’y of Health & Hum. Servs., 35 F.3d

543, 548 (Fed. Cir. 1994). Proof that the proffered medical theory is reasonable, plausible, or

possible does not satisfy a petitioner’s burden. Boatmon v. Sec’y of Health & Hum. Servs., 941

F.3d 1351, 1359-60 (Fed. Cir. 2019).

Petitioners may satisfy the first Althen prong without resort to medical literature,

epidemiological studies, demonstration of a specific mechanism, or a generally accepted medical

theory. Andreu v. Sec’y of Health & Hum. Servs., 569 F.3d 1367, 1378-79 (Fed. Cir. 2009) (citing

Capizzano, 440 F.3d at 1325-26). However, special masters are “entitled to require some indicia

of reliability to support the assertion of the expert witness.” Boatmon, 941 F.3d at 1360, quoting

Moberly, 592 F.3d at 1324. Special Masters, despite their expertise, are not empowered by statute

to conclusively resolve what are complex scientific and medical questions, and thus scientific

evidence offered to establish Althen prong one is viewed “not through the lens of the laboratorian,

but instead from the vantage point of the Vaccine Act’s preponderant evidence standard.” Id. at

1380. Accordingly, special masters must take care not to increase the burden placed on petitioners

in offering a scientific theory linking vaccine to injury. Contreras v. Sec’y of Health & Hum.

Servs., 121 Fed. Cl. 230, 245 (2015), vacated on other grounds, 844 F.3d 1363 (Fed. Cir. 2017);

see also Hock v. Sec’y of Health & Hum. Servs., No. 17-168V, 2020 U.S. Claims LEXIS 2202 at

*52 (Fed. Cl. Spec. Mstr. Sept. 30, 2020).

The second Althen prong requires proof of a logical sequence of cause and effect, usually

supported by facts derived from a petitioner’s medical records. Althen, 418 F.3d at 1278; Andreu,

569 F.3d at 1375-77; Capizzano, 440 F.3d at 1326 (“medical records and medical opinion

testimony are favored in vaccine cases, as treating physicians are likely to be in the best position

to determine whether a ‘logical sequence of cause-and-effect show[s] that the vaccination was the

reason for the injury’”) (quoting Althen, 418 F.3d at 1280). Medical records are generally viewed

as particularly trustworthy evidence, since they are created contemporaneously with the treatment

of the patient. Cucuras v. Sec’y of Health & Hum. Servs., 993 F.2d 1525, 1528 (Fed. Cir. 1993).

However, medical records and/or statements of a treating physician’s views do not per se

bind the special master to adopt the conclusions of such an individual, even if they must be

considered and carefully evaluated. Section 13(b)(1) (providing that “[a]ny such diagnosis,

conclusion, judgment, test result, report, or summary shall not be binding on the special master or

court”). As with expert testimony offered to establish a theory of causation, the opinions or

diagnoses of treating physicians are only as trustworthy as the reasonableness of their suppositions

or bases. The views of treating physicians should also be weighed against other, contrary evidence

also present in the record. Hibbard v. Sec’y of Health & Hum. Servs., 100 Fed. Cl. 742, 749 (2011),

aff’d, 698 F.3d 1355 (Fed. Cir. 2012); Caves v. Sec’y of Health & Hum. Servs., No. 06-522V, 2011

WL 1935813, at *17 (Fed. Cl. Spec. Mstr. Apr. 29, 2011), mot. for review den’d, 100 Fed. Cl. 344,

356 (2011), aff’d without opinion, 475 Fed. App’x 765 (Fed. Cir. 2012).

16

The third Althen prong requires establishing a “proximate temporal relationship” between

the vaccination and the injury alleged. Althen, 418 F.3d at 1281. That term has been equated to

the phrase “medically-acceptable temporal relationship.” Id. A petitioner must offer “preponderant

proof that the onset of symptoms occurred within a timeframe which, given the medical

understanding of the disorder’s etiology, it is medically acceptable to infer causation.” de Bazan

v. Sec’y of Health & Hum. Servs., 539 F.3d 1347, 1352 (Fed. Cir. 2008). The explanation for what

is a medically acceptable timeframe must also coincide with the theory of how the relevant vaccine

can cause an injury (Althen prong one’s requirement). Id. at 1352; Shapiro v. Sec’y of Health &

Hum. Servs., 101 Fed. Cl. 532, 542 (2011), recons. den’d after remand, 105 Fed. Cl. 353 (2012),

aff’d mem., 503 F. App’x 952 (Fed. Cir. 2013); Koehn v. Sec’y of Health & Hum. Servs., No. 11-

355V, 2013 WL 3214877 (Fed. Cl. Spec. Mstr. May 30, 2013), mot. for review den’d (Fed. Cl.

Dec. 3, 2013), aff’d, 773 F.3d 1239 (Fed. Cir. 2014).

B. Law Governing Analysis of Fact Evidence

The process for making factual determinations in Vaccine Program cases begins with

analyzing the medical records, which are required to be filed with the petition. Section 11(c)(2).

The special master is required to consider “all [] relevant medical and scientific evidence contained

in the record,” including “any diagnosis, conclusion, medical judgment, or autopsy or coroner’s

report which is contained in the record regarding the nature, causation, and aggravation of the

petitioner’s illness, disability, injury, condition, or death,” as well as the “results of any diagnostic

or evaluative test which are contained in the record and the summaries and conclusions.” Section

13(b)(1)(A). The special master is then required to weigh the evidence presented, including

contemporaneous medical records and testimony. See Burns v. Sec’y of Health & Hum. Servs., 3

F.3d 413, 417 (Fed. Cir. 1993) (it is within the special master’s discretion to determine whether to

afford greater weight to contemporaneous medical records than to other evidence, such as oral

testimony surrounding the events in question that was given at a later date, provided that such

determination is evidenced by a rational determination).

Medical records created contemporaneously with the events they describe are generally

trustworthy because they “contain information supplied to or by health professionals to facilitate

diagnosis and treatment of medical conditions,” where “accuracy has an extra premium.” Kirby v.

Sec’y of Health & Hum. Servs., 997 F.3d 1378 (Fed. Cir. 2021) citing Cucuras, 993 F.2d at 1528.

This presumption is based on the linked proposition that (i) sick people visit medical professionals;

(ii) sick people honestly report their health problems to those professionals; and (iii) medical

professionals record what they are told or observe when examining their patients in as accurate a

manner as possible, so that they are aware of enough relevant facts to make appropriate treatment

decisions. Sanchez v. Sec’y of Health & Hum. Servs., No. 11-685V, 2013 WL 1880825 at *2 (Fed.

Cl. Spec. Mstr. Apr. 10, 2013), claim den., 2020 WL 5641872 (Fed. Cl. Spec. Mstr. Aug. 26,

2020), rev. den., 152 Fed. Cl. 782 (2021), rev’d and remanded, 34 F.4 th 1350 (Fed. Cir. 2022).

Accordingly, if the medical records are clear, consistent, and complete, then they should

be afforded substantial weight. Lowrie v. Sec’y of Health & Hum. Servs., No. 03-1585V, 2005 WL

6117475 at *20 (Fed. Cl. Spec. Mstr. Dec. 12, 2005). Indeed, contemporaneous medical records

are generally found to be deserving of greater evidentiary weight than oral testimony -- especially

where such testimony conflicts with the record evidence. Cucuras, 993 F.2d at 1528; see also

17

Murphy v. Sec’y of Health & Hum. Servs., 23 Cl. Ct. 726, 733 (1991), aff’d per curiam, 968 F.2d

1226 (Fed. Cir. 1992), cert. den’d, Murphy v. Sullivan, 506 U.S. 974 (1992) (citing United States

v. U.S. Gypsum Co., 333 U.S. 364, 396 (1947) (“[i]t has generally been held that oral testimony

which is in conflict with contemporaneous documents is entitled to little evidentiary weight.”)).

However, there are situations in which compelling oral testimony may be more persuasive

than written records, such as where records are deemed to be incomplete or inaccurate. Campbell

v. Sec’y of Health & Hum. Servs., 69 Fed. Cl. 775, 779 (2006) (“like any norm based upon common

sense and experience, this rule should not be treated as an absolute and must yield where the factual

predicates for its application are weak or lacking”); Lowrie, 2005 WL 6117475 at *19 (“[w]ritten

records which are, themselves, inconsistent, should be accorded less deference than those which

are internally consistent”) (quoting Murphy, 23 Cl. Ct. at 733)). Ultimately, a determination

regarding a witness’s credibility is needed when determining the weight that such testimony should

be afforded. Andreu, 569 F.3d at 1379; Bradley v. Sec’y of Health & Hum. Servs., 991 F.2d 1570,

1575 (Fed. Cir. 1993).

When witness testimony is offered to overcome the presumption of accuracy afforded to

contemporaneous medical records, such testimony must be “consistent, clear, cogent and

compelling.” Sanchez, 2013 WL 1880825 at *3 (citing Blutstein v. Sec’y of Health & Hum. Servs.,

No. 90-2808V, 1998 WL 408611 at *5 (Fed. Cl. Spec. Mstr. June 30, 1998)). In determining the

accuracy and completeness of medical records, the Court of Federal Claims has listed four possible

explanations for inconsistencies between contemporaneously created medical records and later

testimony: (1) a person’s failure to recount to the medical professional everything that happened

during the relevant time period; (2) the medical professional’s failure to document everything

reported to her or him; (3) a person’s faulty recollection of the events when presenting testimony;

or (4) a person’s purposeful recounting of symptoms that did not exist. LaLonde v. Sec’y of Health

& Hum. Servs., 110 Fed. Cl. 184, 203-04 (2013), aff’d, 746 F.3d 1334 (Fed. Cir. 2014). In making

a determination regarding whether to afford greater weight to contemporaneous medical records

or other evidence, such as testimony at hearing, there must be evidence that this decision was the

result of a rational determination. Burns, 3 F.3d at 417.

C. Analysis of Expert Testimony

Establishing a sound and reliable medical theory connecting the vaccine to the injury often

requires a petitioner to present expert testimony in support of her claim. Lampe v. Sec’y of Health

& Hum. Servs., 219 F.3d 1357, 1361 (Fed. Cir. 2000). Vaccine Program expert testimony is usually

evaluated according to the factors for analyzing scientific reliability set forth in Daubert v. Merrell

Dow Pharm., Inc., 509 U.S. 579, 594-96 (1993). See Cedillo v. Sec’y of Health & Hum. Servs.,

617 F.3d 1328, 1339 (Fed. Cir. 2010) (citing Terran v. Sec’y of Health & Hum. Servs., 195 F.3d

1302, 1316 (Fed. Cir. 1999). “The Daubert factors for analyzing the reliability of testimony are:

(1) whether a theory or technique can be (and has been) tested; (2) whether the theory or technique

has been subjected to peer review and publication; (3) whether there is a known or potential rate

of error and whether there are standards for controlling the error; and (4) whether the theory or

technique enjoys general acceptance within a relevant scientific community.” Terran, 195 F.3d at

1316 n.2 (citing Daubert, 509 U.S. at 592-95).

18

The Daubert factors play a slightly different role in Vaccine Program cases than they do

when applied in other federal judicial fora. Daubert factors are employed by judges to exclude

evidence that is unreliable and potentially confusing to a jury. In Vaccine Program cases, these

factors are used in the weighing of the reliability of scientific evidence. Davis v. Sec’y of Health

& Hum. Servs., 94 Fed. Cl. 53, 66-67 (2010) (“uniquely in this Circuit, the Daubert factors have

been employed also as an acceptable evidentiary-gauging tool with respect to persuasiveness of

expert testimony already admitted”).

Respondent frequently offers one or more experts of his own in order to rebut a petitioner’s

case. Where both sides offer expert testimony, a special master’s decision may be “based on the

credibility of the experts and the relative persuasiveness of their competing theories.”

Broekelschen v. Sec’y of Health & Hum. Servs., 618 F.3d 1339, 1347 (Fed. Cir. 2010) (citing

Lampe, 219 F.3d at 1362). However, nothing requires the acceptance of an expert’s conclusion

“connected to existing data only by the ipse dixit of the expert,” especially if “there is simply too

great an analytical gap between the data and the opinion proffered.” Snyder, 88 Fed. Cl. at 743

(quoting Gen. Elec. Co. v. Joiner, 522 U.S. 136, 146 (1997)). A “special master is entitled to

require some indicia of reliability to support the assertion of the expert witness.” Moberly, 592

F.3d at 1324. Weighing the relative persuasiveness of competing expert testimony, based on a

particular expert’s credibility, is part of the overall reliability analysis to which special masters

must subject expert testimony in Vaccine Program cases. Id. at 1325-26 (“[a]ssessments as to the

reliability of expert testimony often turn on credibility determinations”).

D. Consideration of Medical Literature

Although this decision discusses some but not all of the medical literature in detail, I

reviewed and considered all of the medical records and literature submitted in this matter. See

Moriarty v. Sec’y of Health & Hum. Servs., 844 F.3d 1322, 1328 (Fed. Cir. 2016) (“We generally

presume that a special master considered the relevant record evidence even though [s]he does not

explicitly reference such evidence in h[er] decision.”); Simanski v. Sec’y of Health & Hum. Servs.,

115 Fed. Cl. 407, 436 (2014) (“[A] Special Master is ‘not required to discuss every piece of

evidence or testimony in her decision.’” (citation omitted)), aff’d, 601 F. App’x 982 (Fed. Cir.

2015).

VI. Analysis

Because Petitioner does not allege an injury listed on the Vaccine Injury Table, her claim

is classified as “off-Table.” As noted above, to prevail on an “off-Table” claim, Petitioner must

prove by preponderant evidence that she suffered an injury and that this injury was caused by the

vaccination at issue. See Capizzano, 440 F.3d at 1320.

A. Credibility of the Experts

Special masters may consider an expert’s background and expertise when weighing that

expert’s opinion. See Depena v. Sec’y of Health & Hum. Servs., No. 13-675V, 2017 WL 1075101

(Fed. Cl. Spec. Mstr. Feb. 22, 2017), mot. for rev. denied, 133 Fed. Cl. 535, 547-48 (2017), aff’d

without op., 730 Fed. App’x 938 (Fed. Cir. 2018); Copenhaver v. Sec’y of Health & Hum. Servs.,

19

the totality of the case, whether it has been shown by a preponderance of the evidence that a vaccine

caused the [petitioner]’s injury.’” Andreu v. Sec’y of Health & Hum. Servs., 569 F.3d 1367, 1382

(Fed. Cir. 2009) (quoting Knudsen v. Sec’y of Health & Hum. Servs., 35 F.3d 543, 549 (Fed. Cir.

1994)). “Although the Vaccine Act does not require absolute precision, it does require the

petitioner to establish an injury – the Act specifically creates a claim for compensation for

‘vaccine-related injury or death.’” Stillwell v. Sec’y of Health & Hum. Servs., 118 Fed. Cl. 47, 56

(2014) (quoting 42.U.S.C. § 300aa-11(c)). Accordingly, the Federal Circuit has concluded that it

is “appropriate for the special master to first determine what injury, if any, [is] supported by the

evidence presented in the record” before applying a causation analysis pursuant to Althen v.

Secretary of Health & Human Services, 418 F.3d 1274 (Fed. Cir. 2005). Lombardi v. Sec’y of

Health & Hum. Servs., 656 F.3d 1343, 1351-53 (Fed. Cir. 2011).

During the course of this case, Petitioner has alleged that she suffers from various

conditions, to include fibromyalgia, “post vaccination syndrome,” myalgic encephalomyelitis and

chronic fatigue syndrome (ME/CFS), and small fiber neuropathy.

1. Petitioner has not Established that She Suffers from ME/CFS or SFN

a. ME/CFS

In her first expert report filed in this case, Petitioner, through her expert Dr. Bark, alleged

that she suffered from myalgic encephalomyelitis and chronic fatigue syndrome (ME/CFS). In

fact, Dr. Bark contended that “Petitioner has been diagnosed by her treating physicians with a

vaccine-induced Myalgic Encephalomyelitis\Chronic Fatigue Syndrome [ME\CFS] and

Fibromyalgia.” Bark Rep. at 3. This statement is not true in that none of Petitioner’s treating

physicians diagnosed her with ME/CFS. Petitioner’s other expert, Dr. Neuenschwander, opined

that “[t]his is not a case of ME/CFIDS as implied by one of you [sic] other experts.” First

Neuenschwander Rep. at 1. Further, as discussed by Dr. Levinson, Petitioner does not meet the

diagnostic criteria for this disorder. First Levinson Rep. at 7.

The Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue

Syndrome, the Board on the Health of Select Populations, and the Institute of Medicine published

the Proposed Diagnostic Criteria for ME/CFS, reproduced below:

21

however diagnosis should include an assessment of a patient’s symptoms, signs, and diagnostic

test findings. Id. at 7. “Sensory symptoms alone should not be considered a reliable screening

feature.” Devigili et al., Diagnostic criteria for small fibre neuropathy in clinical practice and

research, 142 BRAIN 3728-36 (2019) (filed as Ex. F, Tab 5) (hereinafter “Devigili-2”). Skin biopsy

with quantification of intraepidermal nerve fiber density is the most reliable test to confirm a SFN

diagnosis. Dr. Zhou described it as “the gold standard diagnostic test for small fiber neuropathy

with a high diagnostic efficiency of 88%.” First Zhou Rep. at 8.

Petitioner’s sensory examinations failed to detect the numbness that she reported, and

further, the exams did not consistently show abnormal findings. For example, on September 17,

2014, Petitioner reported tingling and numbness in the feet and hands. However, the sensory exam

conducted by Dr. Bobek was normal. Ex. 2 at 47. Two days later, Dr. Bobek detected allodynia in

her hands, proximal thighs, and trunk. Id. at 56. However, he still did not detect numbness. Id. On

November 3, 2014, Petitioner reported paresthesias, however the physical exam conducted by Dr.

Bobek was normal except that he documented “some tenderness with palpation of the ulnar groove

in the medial left elbow area.” Ex. 2 at 88. Two days later, on November 5, 2014, Dr. Alario and

Dr. Roy noted hyperesthesia in the torso and lateral thigh, however, they documented that her

sensation was “normal to pin”, meaning that she had a normal pinprick test. Ex. 3 at 6. On March

25, 2015, Dr. Scott Friedenberg, a neurologist, conducted a neurologic exam that was entirely

normal. Ex. 3 at 53-54.

In discussing these findings, Dr. Zhou noted that numbness has never been detected at any

medical visit, “which is atypical for significant small fiber degeneration.” First Zhou Rep. at 7. He

summarized by opining: “While the symptoms and signs may suggest small fiber dysfunction, the

exams did not consistently show abnormal sensory findings in the same locations, some of her

symptoms were transient and migrating, so in a case like this, the diagnosis of small fiber

neuropathy cannot be established without confirmatory test findings.” Id. Indeed, none of

Petitioner’s treating physicians diagnosed her with SFN, although several doctors did suggest that

Petitioner rule out other possible disorders through nerve fiber testing. Ex. 3 at 54; Ex. 21 at 7.

There is no indication in the record that this testing was ever performed.

Dr. Neuenschwander based his diagnosis of Petitioner on “the fact that a high percentage

of patients with fibromyalgia have SFN along with the fact that her clinical picture fits the

description of pain caused by SFN.” Second Neuenschwander Rep. at 2. Dr. Neuenschwander,

who is not a neurologist, did not discuss any of Petitioner’s physical examinations and how they

did or did not support his proposed diagnosis. He downplayed the importance of IENFD testing in

an unpersuasive manner by noting that many patients with SFN are not appropriately evaluated,

and that the only way to firmly establish Petitioner’s Tdap vaccine as the cause of her condition

would have been to conduct nerve fiber density testing before and after vaccination. Id.

Ultimately, none of Petitioner’s treating doctors diagnosed her with SFN, her physical

examinations were inconsistent and never documented numbness, and IENFD testing was not

performed. Because of this, I agree with Dr. Zhou that Petitioner has not established by

preponderant evidence that she suffers from small fiber neuropathy. Second Zhou Rep. at 1.

23

2. Post Vaccination Syndrome

It is questionable whether “post vaccination syndrome” constitutes a cognizable injury in

the Vaccine Program. No treating physician or expert has provided a set of diagnostic criteria for

“post vaccination syndrome” or discussed how Petitioner’s symptoms met these criteria.

Accordingly, it is not possible to assess whether this is a condition that Petitioner developed.

Broekelschen, 618 F.3d at 1346; Lombardi, 656 F.3d at 1352-1353 (“under Broekelschen,

identification of a petitioner’s injury is a prerequisite to an Althen analysis of causation,” and “the

statute places the burden on the petitioner to make a showing of at least one defined and recognized

injury”).

Aside from my concerns with the vagueness of this proposed condition, I find that the

symptoms Petitioner experienced are best explained by her diagnosis of fibromyalgia.

3. Petitioner’s Fibromyalgia Diagnosis is Supported by the Record

Fibromyalgia is a pain syndrome characterized by widespread pain distribution, tenderness,

hyperalgesia, subjective swelling, and paresthesias. Rose Rep. at 9; Leslie Crofford, Fibromyalgia,

in HARRISON’S PRINCIPLES OF INTERNAL MEDICINE (J. Larry Jameson, et al., eds., 20 th ed. 2018)

(filed as Ex. A, Tab 1). Dr. Levinson opined that Petitioner’s symptoms of widespread pain

involving both sides of the body, pins and needles, hypersensitivity to touch, subjective feelings

of swelling, headaches, irritable bowel syndrome, tiredness, anxiety, and depression were all

“classic for the diagnosis of fibromyalgia.” First Levinson Rep. at 6.

Petitioner’s treating rheumatologist, Dr. Denio, diagnosed her with fibromyalgia. Ex. 3 at

31. All the experts (except Dr. Bark) agree with this diagnosis. Dr. Rose, a rheumatologist, opined

that “[b]ased on the 1990 American College of Rheumatology diagnostic criteria for fibromyalgia

(1) as well as the 2012 and 2016 revisions there is no doubt in my mind that on 1/20/2015 when

she was evaluated by Dr. Denio she could be classified as suffering from this painful condition.”

Rose Rep. at 8. Accordingly, I find Petitioner’s fibromyalgia diagnosis is supported by

preponderant evidence.

4. Althen Prong One

Under Althen prong one, a petitioner must provide a “reputable medical theory,”

demonstrating that the vaccine received can cause the type of injury alleged. Pafford, 451 F.3d at

1355-56 (citations omitted). To satisfy this prong, a petitioner’s theory must be based on a “sound

and reliable medical or scientific explanation.” Knudsen v. Sec'y of Health & Hum. Servs., 35 F.3d

543, 548 (Fed. Cir. 1994). Proof that the proffered medical theory is plausible or possible does not

satisfy a petitioner’s burden. Boatmon v. Sec’y of Health & Hum. Servs., 941 F.3d 1351, 1359-60

(Fed. Cir. Nov. 7, 2019).

A petitioner may satisfy this prong without resort to medical literature, epidemiological

studies, demonstration of a specific mechanism, or a generally accepted medical theory. Andreu v.

Sec’y of Health & Hum. Servs., 569 F.3d 1367, 1378-79 (Fed. Cir. 2009) (citing Capizzano, 440

F.3d at 1325-26). However, special masters are “entitled to require some indicia of reliability to

24

support the assertion of the expert witness.” Boatmon, 941 F.3d at 1360, quoting Moberly, 592

F.3d at 1324. Special Masters, despite their expertise, are not empowered by statute to conclusively

resolve what are complex scientific and medical questions, and thus scientific evidence offered to

establish Althen prong one is viewed “not through the lens of the laboratorian, but instead from

the vantage point of the Vaccine Act’s preponderant evidence standard.” Id. at 1380. Accordingly,

special masters must take care not to increase the burden placed on petitioners in offering a

scientific theory linking vaccine to injury. Contreras v. Sec’y of Health & Hum. Servs., 121 Fed.

Cl. 230, 245 (2015), vacated on other grounds, 844 F.3d 1363 (Fed. Cir. 2017); see also Hock v.

Sec’y of Health & Hum. Servs., No. 17-168V, 2020 U.S. Claims LEXIS 2202 at *52 (Fed. Cl.

Spec. Mstr. Sept. 30, 2020). Because I have concluded that Petitioner’s correct diagnosis is

fibromyalgia, I will consider whether Petitioner has presented preponderant evidence that the Tdap

vaccine can cause that condition.

Dr. Bark and Dr. Neuenschwander propose similar theories of causation: the Tdap vaccine

led Petitioner to develop endoplasmic reticulum stress, which in turn resulted in chronic immune

overactivation, which caused her condition (Dr. Bark) versus chronic activation of the cell danger

response through an overreaction to the Tdap vaccine (Dr. Neuenschwander).

Petitioner’s theory is vague and unsupported. According to Dr. Bark, “ER HyperStress

results from a combination of genetics risk factors petitioner had, coupled with environmental

exposures (aluminum hydroxy), which together can cause cellular death and pathological

outcomes experienced by petitioner.” Bark Rep. at 3. However, as noted by Dr. Levinson, Dr. Bark

did not explain which cells were killed in Petitioner’s tissues or how the death of these cells caused

her condition. First Levinson Rep. at 13. Dr. Neuenschwander’s favored theory, “immune over-

activation and subsequent exacerbation of pre-existing autoimmunity,” (First Neuenschwander

Rep. at 5) aside from the unsupported assumption that Petitioner experienced an immune over-

activation, does not explain what caused the persistence of the oxidative stress or how that took

place. In fact, nowhere did either of Petitioner’s experts explain how the Tdap vaccine resulted in

Petitioner’s chronic condition.

Further reducing the persuasiveness of Petitioner’s causal theory is its “aluminum toxicity”

component. While Petitioner filed medical literature suggesting that under some circumstances,

aluminum can negatively impact cell function, “[t]here is no reason to believe that the effect of

aluminum on vitro cultured astrocytes, neuroblastoma cells or hepatic cells translates to the alleged

in vivo effects of a single injection of 0.33 mg of aluminum hydroxide into the deltoid muscle of

a human.” First Levinson Rep. at 15. Petitioner’s medical literature even illustrates the low level

of aluminum exposure from vaccines when compared with other sources, to include “air

inhalation”:

Table 2 Al exposure from alternate source (adapted from Yokel et al. 2008)

Source Al exposure

Antacids 5,000,000 μg/day

Air inhalation 4–20 μg/day

Industrial air inhalation 25,000 μg/day

25

Antiperspirants 70,000 μg/day

Cigarettes 500–2,000 μg/cigarette

Vaccines 1–8 μg/day

Allergy immunotherapy 7–40 μg/day

Sung Han et al., How aluminum, an intracellular ROS generator promotes hepatic and

neurological diseases: the metabolic tale, 29 CELL BIOLOGY & TOXICOLOGY 75-84, 76 (2013)

(filed as Ex. 9). Dr. Neuenschwander seemingly eschewed a theory involving direct toxicity of

aluminum, noting “I will not press this as a cause, because there is a lack of direct evidence in

Francis’ situation.” First Neuenschwander Rep. at 5.

I further note that the autoimmune syndrome induced by adjuvants or “ASIA” theory has

not been found to be sufficient to satisfy Althen prong one. See, e.g., Monzon v. Sec’y of Health &

Hum. Servs., No. 17-1055V, 2021 WL 2711289, at *8 n.6 (Fed. Cl. Spec. Mstr. June 2,

2021); Garner v. Sec’y of Health & Hum. Servs., No. 15-0063V, 2017 WL 1713184, at *15 (Fed.

Cl. Spec. Mstr. Mar. 24, 2017); Johnson v. Sec’y of Health & Hum. Servs., No. 10-0578V, 2016

WL 4917548, at *8-9 (Fed. Cl. Spec. Mstr. Aug. 18, 2016) (describing this theory as overbroad,

generalized, and vague and finding this expansive theory logically unpersuasive); Morris v. Sec’y

of Health & Hum. Servs., No. 12-415V, 2016 WL 3022141, at *12 (Fed. Cl. Spec. Mstr. Apr. 1,

2016) (discussing lack of reliability of ASIA theory); Rowan v. Sec’y of Health & Hum.

Servs., No. 10-272V, 2014 WL 7465661, at *16 (Fed. Cl. Spec. Mstr. Dec. 8, 2014), mot. for

review den’d, 2015 WL 3562409 (Fed. Cl. May 18, 2015); D’Angiolini v. Sec’y of Health & Hum.

Servs., No. 99-578V, 2014 WL 1678145, at *60 (Fed. Cl. Spec. Mstr. Mar. 27, 2014), mot. for

review den’d, 122 Fed. Cl. 86 (2015), aff’d, 645 F. App’x 1002 (Fed. Cir. 2016).

I additionally find that Petitioner’s prong one showing is deficient because fibromyalgia is

generally not considered to be an autoimmune disease, and thus is unlikely to result from

vaccination. Rose Rep. at 9, 12-13; First Levinson Rep. at 13; see also, Mattus-Lang v. Sec’y of

Health & Hum. Servs., No. 15-113V, 2022 WL 4242140 (Fed. Cl. Spec. Mstr. Aug. 31, 2022)

(finding insufficient evidence that a child’s seizures had an autoimmune etiology, and therefore

determining they could not be vaccine caused); H.C. v. Sec’y of Health & Hum. Servs., No. 16-

4V, 2022 WL 2825395 (Fed. Cl. Spec. Mstr. May 9, 2022) (concluding that because Ramsay Hunt

is not an autoimmune disease, molecular mimicry was not an applicable Althen prong one theory);

McKown v. Sec’y of Health & Hum. Servs., No. 15-1451V, 2019 WL 4072113 (Fed. Cl. Spec.

Mstr. Jul. 15, 2019) (finding that POTS is usually not an autoimmune condition “greatly reducing

the likelihood that a vaccine could initiate an autoimmune process sufficient to cause it.”). The

point that fibromyalgia does not have an autoimmune etiology is supported by the common

therapies for the condition, which include cognitive behavioral therapy, as well as Cymbalta and

Lyrica, therapies which target pain modulation, as opposed to anti-inflammatories or

immunosuppressing drugs. Rose Rep. at 9-10, 13.

Ultimately, and based on the foregoing, Petitioner has not provided preponderant evidence

in support of the first Althen prong.

26

5. Althen Prong Two 10

Althen prong two requires Petitioner to establish a logical sequence of cause and effect

demonstrating that the vaccination did cause her condition. Althen, 418 F.3d at 1278; Andreu, 569

F.3d at 1375-77; Capizzano, 440 F.3d at 1326 (“medical records and medical opinion testimony

are favored in vaccine cases, as treating physicians are likely to be in the best position to determine

whether a ‘logical sequence of cause-and-effect show[s] that the vaccination was the reason for

the injury’”) (quoting Althen, 418 F.3d at 1280). Medical records are generally viewed as

particularly trustworthy evidence, since they are created contemporaneously with the treatment of

the patient. Cucuras v. Sec’y of Health & Hum. Servs., 993 F.2d 1525, 1528 (Fed. Cir. 1993).

In weighing evidence, special masters are expected to consider the views of treating

doctors. Capizzano, 440 F.3d at 1326. The views of treating doctors about the appropriate

diagnosis are often persuasive because the doctors have direct experience with the patient whom

they are diagnosing. See McCulloch v. Sec’y of Health & Hum. Servs., No. 09-293V, 2015 WL

3640610, at *20 (Fed. Cl. Spec. Mstr. May 22, 2015).

Dr. Bobek, Petitioner’s PCP, diagnosed her with a reaction to vaccination. Ex. 2 at 18.

Petitioner’s rheumatologist, Dr. Denio, noted that Petitioner’s fibromyalgia “appears to have been

triggered by a reaction to a Tdap vaccine last July.” Ex. 3 at 31. Several other doctors were less

committal. For example, Dr. Friedenberg opined that Petitioner had experienced “many years of

multiple multifocal neurologic symptoms without etiology identified” and then questioned

whether her symptoms were caused by the Tdap vaccine. Ex. 3 at 53. Dr. Preston stated that the

“[n]ew onset of GERD symptoms [was] unlikely related to vaccination.” Ex. 3 at 23.

Although several of Petitioner’s treating physicians linked the Tdap vaccine with her

condition, I am not obliged to adopt the same view. See 42 U.S.C. §§ 300aa-13(b)(1) (providing

that “[a]ny such diagnosis, conclusion, judgment, test result, report, or summary shall not be

binding on the special master or court”); Snyder v. Sec’y of Health & Hum. Servs., 88 Fed. Cl. 706,

746 n.67 (2009) (“there is nothing . . . that mandates that the testimony of a treating physician is

sacrosanct—that it must be accepted in its entirety and cannot be rebutted.”). Dr. Bobek and Dr.

Denio do not provide a rationale for their opinions, which renders them less persuasive. Ultimately,

10 I note that there is some evidence in the medical records that Petitioner had symptoms consistent with

fibromyalgia long before vaccination. On January 20, 2015, Petitioner visited Dr. Denio, who documented

that “[t]he patient has been to Rheumatology a couple of times before variously for some diffuse myalgias

and arthralgias, the last time in 2002 for some paresthesias in the left hand thought to be on the basis of

carpal tunnel syndrome, although the nerve conduction testing at that time was negative.” Ex. 3 at 32. On

March 25, 2015, Dr. Friedenberg documented that Petitioner had experienced “many years of multiple

multifocal neurologic symptoms without etiology identified, sx ppt by recent vaccine? And her flare ups of

disease are short lived in past, with vaccination sx have persisted.” Ex. 3 at 53. Petitioner was ultimately

unable to produce these prior rheumatology records. Accordingly, Dr. Rose opined: “I cannot offer more

details regarding the precise time of onset of her fibromyalgia, although it appears to be a problem in her

for a long time.” Rose Rep. at 8. Although the note in the medical records from Dr. Denio and Dr.

Friedenberg constitutes some evidence that Petitioner may have developed fibromyalgia in the past, the

absence of these records prevents further meaningful analysis.

27

while I have considered these opinions in my analysis of Petitioner’s case, I find that this evidence

does not preponderantly establish that the Tdap vaccine did cause Petitioner’s condition.

Additionally, several components of Petitioner’s case diminish the persuasiveness of her

showing. For instance, Petitioner’s theory of the case emphasizes the fact that she had a prior

severe adverse reaction to the Tdap vaccine, and that this, in part, caused her to have “a systemic

and autoimmune response to the [July 29, 2014] Tdap vaccine.” (Pet’r’s Mot. at 19; see also, Bark

Rep. at 3, noting that Petitioner’s prior reaction to the prior Tdap vaccine was “serious”). For

reasons that are unclear, Petitioner filed the package insert for the Pediarix vaccine, the formulation

administered to infants and young children. Ex. 25. That package insert describes that an example

of a severe allergic reaction is anaphylaxis. Ex. 25 at 1. Petitioner did not experience anaphylaxis

post vaccination. Dr. Levinson described that common side effects of the Tdap vaccine include

“pain and swelling at the injection site, low-grade fever, headache, malaise, abdominal discomfort

including nausea, vomiting or diarrhea, myalgias, and lymphadenopathy.” First Levinson Rep. at

7. Petitioner did experience these symptoms; accordingly, her prior reaction should not be

characterized as severe or serious.

Further, there is no indication that Petitioner’s condition was caused by an autoimmune

process. When measured around November of 2014, her ESR was normal and her ANA was

negative. Ex. 3 at 4. These results do not provide support for Dr. Bark’s and Dr. Neuenschwander’s

theories of robust and chronic immune activation. As Dr. Levinson stated, “[t]here is not a single

diagnostic immunological test result in her medical records (including biomarkers of underling

inflammation like erythrocyte sedimentation rate and C-reactive protein) that suggested an

underlying autoimmune or inflammatory process other than her pre-existing thyroiditis.” Second

Levinson Rep. at 5. Petitioner has not presented preponderant evidence in support of Althen prong

two.

6. Althen Prong Three

Althen prong three requires a petitioner to establish a “proximate temporal relationship”

between her condition and the vaccine she received. Althen, 418 F.3d at 1281. Petitioner must offer

“preponderant proof that the onset of symptoms occurred within a timeframe which, given the

medical understanding of the disorder’s etiology, it is medically acceptable to infer causation.” de

Bazan v. Sec’y of Health & Hum. Servs., 539 F.3d 1347, 1352 (Fed. Cir. 2008).

The timing prong contains two parts. First, Petitioner must establish the “timeframe for

which it is medically acceptable to infer causation” and second, she must demonstrate that the

onset of the disease occurred in this period. Shapiro v. Secʼy of Health & Hum. Servs., 101 Fed.

Cl. 532, 542-43 (2011), recons. denied after remand on other grounds, 105 Fed. Cl. 353 (2012),

aff’d without op., 503 F. App’x 952 (Fed. Cir. 2013).

Because Althen prong three coincides with Althen prong one, Petitioner’s inability to meet

her burden demonstrating how the Tdap vaccine can cause fibromyalgia effectively precludes her

from being able to meet her burden under the third Althen prong. Thus, because I have found that

Petitioner did not offer a sound and reliable theory of causation, she cannot demonstrate that her

condition arose in a medically acceptable timeframe pursuant to that theory. Even assuming that

28

Petitioner satisfied Althen prong three, that alone would not satisfy Petitioner’s overall burden of

proof. Veryzer v. Sec’y of Health & Hum. Servs., 100 Fed. Cl. 344, 356 (2011) (explaining that a

“temporal relationship alone will not demonstrate the requisite causal link and that petitioner must

posit a medical theory causally connecting the vaccine and injury.”).

However, in this particular case, Petitioner’s showing with respect to the third Althen prong

is deficient. Dr. Bark briefly discussed the timing element in her expert report.

In meeting Althen Three, by examining the timing of the exposure and the timing

of the onset of the injuries, these factors combined would be inconsistent with

causation for any other alternative theory of injury. In other words, it is more likely

than not, the TDaP caused the injury in this case because of the dosing and exposure

to the toxins, no other intervening cause identified, and because of the proximate

relationship between vaccination and injury (less than 48 hours). Pet.’s Exh. 1 & 2.

Therefore, it is impossible in this case to rule out the TDaP vaccination, as the cause

of the injuries from the antigen and aluminum hydroxide found in the vaccine.

Bark Rep. at 2. Dr. Bark opined that because Petitioner’s onset of symptoms began 48 hours after

vaccination and no other source of injury has been identified, the vaccine must have caused her

condition. She provides no other rationale for her opinion, except to mention “dosing and exposure

to the toxins.” She did not discuss how this timing was appropriate given her theory of causation.

Similarly, Dr. Neuenschwander did not discuss an appropriate timeframe for his theory of chronic

activation of the danger cell response except to note that “[t]he events clearly are temporally linked

to her Tdap vaccine.” Second Neuenschwander Rep. at 5. The Federal Circuit has explained that

“[a]lthough probative, neither a mere showing of a proximate temporal relationship between

vaccination and injury, nor a simplistic elimination of other potential causes of the injury suffices,

without more, to meet the burden of showing actual causation.” Althen, 418 F.3d at 1278 (citing

Grant, 956 F.2d at 1149).

In opining that Petitioner has not satisfied the third Althen prong, Dr. Rose noted that the

pathogenesis of fibromyalgia likely involves “alterations of neurobiological pathways affecting

the central nervous system, the terminal nerve fiber density in the skin as well as genetic variants

of pain receptors.” Rose Rep. at 9. He persuasively opined that these conditions take time to

develop and would not occur in days or weeks. He stated that “[i]t is important to understand that

the non-genetic abnormalities involving central nervous system connectivity, increased number of

sensory fibers and the like need time to develop and are very likely to begin manifesting as pain

syndromes over the years in individuals like Ms. Ruzicka.” Id. at 11.

Based on the above, I find that Petitioner has not presented preponderant evidence in

support of the timeframe for which it is medically acceptable to infer causation. She has not met

Althen prong three.

VII. Conclusion

Upon careful evaluation of all the evidence submitted in this matter, including the medical

records, the affidavits, as well as the experts’ opinions and medical literature, I conclude that

29

Petitioner has not shown by preponderant evidence that she is entitled to compensation under the

Vaccine Act. Her petition is therefore DISMISSED. The clerk shall enter judgment

accordingly. 11

IT IS SO ORDERED.

s/ Katherine E. Oler

Katherine E. Oler

Special Master

11 Pursuant to Vaccine Rule 11(a), the parties may expedite entry of judgment by each filing (either jointly

or separately) a notice renouncing their right to seek review.

30